Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 known ✓ | P09237 | 1/20 | 0.72 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.72 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.72 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.72 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.72 |
| ▸ | MEN1 known ✓ | O00255 | 6/20 | 0.47 |
| ▸ | THRB known ✓ | P10828 | 5/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.72 |
| ▸ | MMP3 | P08254 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.70 |
| ▸ | USP2 | O75604 | 6/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.69 |
| ▸ | RECQL | P46063 | 7/20 | 0.67 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.67 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1649970 | 0.98 | MMP2 (0.74) | MMP2MMP3MMP7MMP8ADORA1 | |
| SCHEMBL40930 | 0.97 | TDP1 (0.73) | MMP2MMP3MMP7MMP8ADORA1 | |
| SCHEMBL4082631 | 0.97 | TDP1 (0.73) | MMP2MMP3MMP7MMP8ADORA1 | |
| SCHEMBL21014939 | 0.97 | TDP1 (0.73) | MMP2MMP3MMP7MMP8ADORA1 | |
| SCHEMBL4082642 | 0.97 | TDP1 (0.73) | MMP2MMP3MMP7MMP8ADORA1 | |
| SCHEMBL23005369 | 0.97 | TDP1 (0.73) | MMP2MMP3MMP7MMP8ADORA1 | |
| SCHEMBL1176275 | 0.97 | TDP1 (0.73) | MMP2MMP3MMP7MMP8ADORA1 | |
| Alcohol SCHEMBL14973542 | 0.97 | KDM4E (0.72) | MMP2MMP3MMP7MMP8ADORA1 | |
| SCHEMBL18610140 | 0.90 | TDP1 (0.65) | MMP2MMP3MMP7MMP8ADORA1 | |
| Water SCHEMBL29358570 | 0.83 | MMP2 (1.00) | MMP2MMP3MMP7MMP8ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227999-B2 | Antimicrobial cationic peptides and formulations thereof | CARRUS CAPITAL CORPORATION (CA) | 2016-01-05 | — | — | US | claimed |
| CN-119950523-B | Doxycycline hydrochloride and clavulanate potassium powder for aquatic products and preparation method and application thereof | YANGTZE RIVER FISHERIES RESEARCH INSTITUTE CHINESE ACADEMY OF FISHERY SCIENCES (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-3866826-B1 | ANTIMICROBIAL PEPTIDES AND METHODS OF USING THE SAME | RIPTIDE BIOSCIENCE INC (US) | 2025-12-10 | — | — | EP | disclosed |
| CN-119979581-A | Whole-cell biosensor for detecting tetracycline in environmental water body and application thereof | 华东师范大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-119950523-A | Doxycycline hydrochloride and clavulanate potassium powder for aquatic products and preparation method and application thereof | 中国水产科学研究院长江水产研究所 | 2025-05-09 | — | — | CN | disclosed |
| US-20240299291-A1 | OPHTHALMIC PREPARATION ADMINISTERED BY EYE DROPS AND USED FOR PREVENTING AND TREATING DRY MACULAR DEGENERATION AND RETINAL LIGHT DAMAGE | Chengdu Ruimu Biopharmaceuticals Co., Ltd. (CN) | 2024-09-12 | — | — | US | disclosed |
| WO-2024186695-A2 | IMMUNE CELL FUSION (ICF) AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240293462-A1 | Immune Cell Fusion (ICF) and Uses Thereof | TRUSTEES OF BOSTON UNIVERSITY | 2024-09-05 | — | — | US | disclosed |
| US-12031977-B2 | Ex vivo system for determining multiple drug-drug transporter interactions and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240209370-A1 | METHODS OF MODULATING ALK | Société des Produits Nestlé S.A. (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-0925308-B1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH INC (CA) | 2002-06-05 | — | — | EP | disclosed |
| US-20020035061-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | BIOWEST THERAPEUTICS INC. (CA) | 2002-03-21 | — | — | US | disclosed |
| EP-1174439-A2 | Compositions and methods for treating infections using analogues of indolicidin | Micrologix Biotech, Inc. (CA) | 2002-01-23 | — | — | EP | disclosed |
| US-6180604-B1 | Compositions and methods for treating infections using analogues of indolicidin | MICROLOGIX BIOTECH INC. (CA) | 2001-01-30 | — | — | US | disclosed |
| EP-0966481-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | Micrologix Biotech, Inc. (CA) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999065506-A2 | CANCER THERAPY WITH INDOLICIDIN OR CATIONIC PEPTIDES AND THEIR POLYMER CONJUGATES | MICROLOGIX BIOTECH INC. (CA) | 1999-12-23 | — | — | WO | disclosed |
| EP-0925308-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | Micrologix Biotech, Inc. (CA) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998040401-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | MICROLOGIX BIOTECH INC. (CA) | 1998-09-17 | — | — | WO | disclosed |
| WO-1998007745-A9 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | — | 1998-04-23 | — | — | WO | disclosed |
| WO-1998007745-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH, INC. (CA) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035061-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | VIP, PEPD, PTMS | MMP7 212/4885MMP8 44/4885ADORA1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.